Preview Newsletter
Xarelto Media Monitoring Week of 4/10/2015
-
Xarelto Litigation Update: Legal-Bay Lawsuit Settlement Funding Reports Issuance of New Court Documents
Apr 7, 2015 | PR Newswire
By Legal-Bay LLC
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that two new court documents were issued in consolidated litigations regarding Xarelto in Pennsylvania and Louisiana. According to court documents, a court order dated March 24th for the U.S. District Court in the Eastern District of Louisiana, where the federal multidistrict litigation (MDL) for Xarelto is being overseen, indicates that plaintiffs will now be able to file cases directly in the proceeding (In Re: Xarelto Products Liability Litigation, No. 2592). Also, in the Philadelphia Court of Common Pleas in Pennsylvania, court documents from March 23rd show that plaintiffs who have claims and want to file suits will be able to use a Master Long Form Complaint in Pennsylvania's (PA) mass tort proceeding for Xarelto (In Re: Xarelto Litigation, Case ID 150102349). -
Xarelto Attorneys: Pretrial Update on National Xarelto Lawsuits
Apr 7, 2015 | PR Web
By Onder Law Firm
Attorneys handling national Xarelto lawsuits report progress in the multidistrict litigation* now underway in United States District Court in the Eastern District of Louisiana. According to court documents, a Status Conference was held on April 1, 2015 during which multiple topics were addressed including coordination between U.S. District Court and various state courts where Xarelto lawsuits are also underway, and discovery procedures. Xarelto lawyers provide regular Xarelto lawsuit news updates and detailed information about Xarelto side effects at their website, XareltoContingencyLawsuitCenter.com. -
Fraudulent Misrepresentation Alleged in Xarelto Lawsuit
Apr 9, 2015 | Injury Lawyer News
By Jacky Gale
A new Xarelto lawsuit has been filed against Janssen Research & Development, Johnson & Johnson, Janssen Pharmaceuticals, and Bayer Healthcare Pharmaceuticals, Inc., et al. The complaint was filed on behalf of Lola Carson, an Ohio resident, and Allen H. Cleland, deceased. -
Coordination of Xarelto Bleeding Lawsuits Sought Between State and Federal Courts
Apr 9, 2015 | About Lawsuits
By Austin Kirk
As a growing number of Xarelto lawsuits continue to be filed on behalf of individuals throughout the country who have suffered severe or fatal bleeding problems, the parties involved in the cases are continuing to work to coordinate the litigation between the state and federal courts. -
Rhode Island Man Sues Xarelto Over Bleeding Risks
Apr 9, 2015 | Righting Injustice
By Jennifer Walker-Journey
A Rhode Island man is suing the makers of the blood thinner Xarelto claiming the manufacturers misled the public by marketing the drug as safe while not revealing the odds of serious bleeding side effects associated with the drug. The lawsuit also claims that no antidote is available to reverse the blood thinning effects once uncontrolled bleeding occurs. -
MEYERKORD & MEYERKORD Currently Representing XARELTO Cases
Apr 9, 2015 | St. Louis Personal Injury Lawyer
By Meyerkord & Meyerkord LLC
Furthermore, Xarelto is a more popular choice among users because it offers a more convenient option for patients by not needing routine blood monitoring, and opening a broader range of food while taking it. Tragically, although Xarelto gives patients more life-style choices and ease, it is damaging as well. For instance, many patients are experiencing life threatening bleeding episodes while taking Xarelto. Likewise, there is no antidote to stop bleeding once it's began unlike other blood thinners on the market. Coumadin bleeding can be stopped with a dose of vitamin K, yet currently Xarelto makers have no such mechanism to stop patients from bleeding to death. Now, some patients are becoming severely injured, and even dying as a result of taking Xarelto. Victims and their family members are seeking answers, and looking to the justice system to help. -
Ala. Man Sues Pharmaceutical Giants over Xarelto Bleeding
Apr 9, 2015 | Top Class Actions
By Amanda Antell
Alabama plaintiff Richard E. is suing Bayer and Janssen Pharmaceuticals for the injuries he allegedly suffered after taking Xarelto. Richard claims that in direct result of taking the medication, he suffered severe Xarelto bleeding injuries that required emergency hospitalization. -
Does Xarelto Cause Uncontrollable Bleeding?
Apr 9, 2015 | The Legal Examiner
By Shezad Malik MD JD
The short answer is yes, if you believe the allegations in the over 300 lawsuits filed to date. Xarelto is one of the newer oral anticoagulant medications that has been approved by the FDA. The federal Xarelto personal injury and product liability claims are centralized before U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana. -
Xarelto makers sued by Texas woman
Apr 8, 2015 | Williams Kherkher Attorneys
A plaintiff from Texas recently filed a lawsuit against Xarelto makers in St. Clair County Circuit Court claiming she suffered injuries as a result of using the potentially dangerous drug, Madison-St. Clair Record stated on April 6. -
Xarelto Causes Life-Threatening Internal Bleeding, Lawsuit Claims
Apr 7, 2015 | Top Class Actions
By Melissa LaFreniere
The global anticoagulant leader Xarelto is under scrutiny once again as an Alabama resident files lawsuit against its manufacturer Janssen Pharmaceutical, alleging the drug causes life-threatening internal bleeding. -
XARELTO Bleeding Risks
Apr 7, 2015 | The Lieser Law Firm
Many of you may have seen commercials for and against the drug, Xarelto, on TV. Xarelto is blood-thinning drug used to prevent blood clots in patients who have had surgery or are at risk for a blood clot or stroke. Anticoagulants, such as Xarelto, are supposed to make sure that your blood will continue to circulate through your body. Millions of Americans rely on blood thinners every day, but Xarelto is a fairly new drug on the market. Unfortunately, Xarelto comes with a unique set of health risks that have brought on product liability lawsuits for bleeding. -
Xarelto still Brings Big Money to Johnson & Johnson
Apr 6, 2015 | Xarelto Lawsuit
By Flood Law Group, LLP and Gacovino, Lake & Associates, P.C
A growing number of Americans have claimed that Johnson & Johnson, makers of the blood thinner Xarelto, failed to warn of serious and potentially fatal internal bleeding side effects of the drug. In fact, at least 86 Xarelto lawsuits have been consolidated into a multidistrict litigation (MDL) in Louisiana. Despite the negative attention garnered by these lawsuits and allegations, the Xarelto still earned more than $1 billion for J&J last year. -
Was Xarelto Approved Based on Faulty Data?
Apr 6, 2015 | The Legal Examiner
By Eric T. Chaffin
Just how accurate are the clinical trials that are submitted to the FDA for drug approvals? According to a recent study in JAMA Internal Medicine, there may be a number of errors, or “departures from good clinical practice” in these studies. These are seldom reported in peer-reviewed literature, leaving doctors and consumers in the dark. This could be particularly serious, as many of the clinical trials in the studies were those that formed the basis for later drug approvals. One of those drugs—Xarelto—was approved despite what has now been called a study full of transgressions, a study that was deemed unreliable by the FDA. -
Intracranial Hemorrhage Subject of Xarelto Lawsuit
Apr 3, 2015 | Drug Reporter
By Eisbrouch Marsh LLC
For patients suffering from the condition known as atrial fibrillation – or “A-fib” – an anti-coagulant drug is often used to help prevent the formation of deadly blood clots. For generations, doctors prescribed the drug known as warfarin to A-fib patients, until the newer blood thinning drug Xarelto was introduced to the market in 2011. -
Bleeding-Induced Heart Attack Leads to Xarelto Class Action Lawsuit
Apr 10, 2015 | The Legal Examiner
By Eric T. Chaffin
All U.S. federal Xarelto lawsuits were consolidated in one court in the Eastern District of Louisiana in December 2014. Now, plaintiffs have filed a new Xarelto class action case in Canada, seeking to gain compensation for Canadian patients who took the drug and later suffered serious side effects.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
OUS Litigation
Full Text of Stories Below
-
Apr 7, 2015 | PR Newswire
By Legal-Bay LLC
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that two new court documents were issued in consolidated litigations regarding Xarelto in Pennsylvania and Louisiana. According to court documents, a court order datedMarch 24th for the U.S. District Court in the Eastern District of Louisiana, where the federal multidistrict litigation (MDL) for Xarelto is being overseen, indicates that plaintiffs will now be able to file cases directly in the proceeding (In Re: Xarelto Products Liability Litigation, No. 2592). Also, in the Philadelphia Court of Common Pleas in Pennsylvania, court documents from March 23rd show that plaintiffs who have claims and want to file suits will be able to use a Master Long Form Complaint in Pennsylvania's (PA) mass tort proceeding for Xarelto (In Re: Xarelto Litigation, Case ID 150102349).
Currently, according to court documents, there are more than 300 lawsuits filed over Xarelto just in the federal litigation in Louisiana, while there are about 160 known cases as of now with similar claims pending in Pennsylvania's mass tort proceeding. The lawsuits against Bayer and Johnson & johnson's Janssen Pharmaceutical Division include claims of serious health problems and even death as a result of using the blood thinner, Xarelto, because of uncontrollable bleeding events. According to experts, there is no known antidote at this time. In light of the recent announcements, Legal-Bay, a law cash advance company, is reaffirming the fact that they are sufficiently prepared to handle large Xarelto pre-settlement funding requests for those who have experienced complications from using the blood thinner.
Chris Janish, CEO of Legal-Bay, commented on the recent announcement of the issuance of the two court documents, "Although this litigation is in the early stages and J&J continues to defend liability aggressively, we are one of the only companies in the legal funding industry stepping up to assist Xarelto patients with getting some financial relief today while their cases drag through the courts. Our Xarelto lawsuit cash advance program enables plaintiffs to access funds throughout the duration of their case, which could take years to resolve. At this point, it is uncertain if there will ever be a settlement in this case; however, settlement amounts in the Pradaxa blood thinner litigation saw an average settlement value of $160K per case, and we believe the values in Xarelto could be similar if a jury were to side with the plaintiffs."
In order to receive lawsuit funding you must have retained a Xarelto lawyer first. If you need lawsuit money or pre-settlement funding for your Xarelto claim, Legal-Bay is here to help. Legal-Bay is offering pre-settlement and settlement funding for Xarelto cases as well as other blood thinners – such as Pradaxa – and they are also providing free legal consultations for possible plaintiffs who have not yet retained a Xarelto lawyer. To learn more about Xarelto, Pradaxa, and other blood thinner cases, including services in helping you find a Xarelto lawyer or Xarelto law firm, visit:http://lawsuitssettlementfunding.com/pradaxa-settlement-funding.php
Legal-Bay is advising victims who have suffered with complications after using the blood thinner, Xarelto, to seek immediate legal counsel to determine if they may have a potential claim against Bayer and Johnson & Johnson's Janssen Pharmaceutical Division. Legal-Bay's representatives can put you in touch with a Xarelto attorney who will provide you with a free legal consultation and you will never pay a fee unless your case is successful. Legal-Bay also provides funding and lawsuit help services for other drug cases as well as defective product cases. For more information or assistance with finding a qualified Xarelto law firm or Xarelto lawyer, contact Legal-Bay directly at:http://lawsuitssettlementfunding.com/contact-us.php
To speak with a live agent right now to discuss receiving pre-settlement lawsuit money or a free legal consultation on your potential Xarelto or Pradaxa blood thinner lawsuit, call Legal-Bay's toll-free hotline at: 877.571.0405. You may also apply online at: http://lawsuitssettlementfunding.com and an agent will respond to your request shortly.
Legal-Bay LLC (and their related companies) is not a law firm and cannot provide legal advice on a consumer's case; however, Legal-Bay works with lawyers involved in mass tort litigations who can provide a free legal consultation at the consumer's direction.
Link: http://www.prnewswire.com/news-releases/xarelto-litigation-update-legal-bay-lawsuit-settlement-funding-reports-issuance-of-new-court-documents-300061032.html
-
Xarelto Attorneys: Pretrial Update on National Xarelto Lawsuits
Apr 7, 2015 | PR Web
By Onder Law Firm
Attorneys handling national Xarelto lawsuits report progress in the multidistrict litigation* now underway in United States District Court in the Eastern District of Louisiana. According to court documents, a Status Conference was held on April 1, 2015 during which multiple topics were addressed including coordination between U.S. District Court and various state courts where Xarelto lawsuits are also underway, and discovery procedures. Xarelto lawyers provide regular Xarelto lawsuit news updates and detailed information about Xarelto side effects at their website, XareltoContingencyLawsuitCenter.com.
Xarelto lawsuits alleging the drug had caused severe internal bleeding and hemorrhagic stroke were first consolidated in Louisiana in December of 2014. The litigation, known as Xarelto (Rivaroxaban) Products Liability Litigation now includes a total of 311 pending actions which have originated throughout the nation, according to court documents as of April 6, 2015.
Each of these 311 actions shares common questions of fact, alleging that Xarelto caused severe internal bleeding, stroke, or another serious health issue, in each of the plaintiffs, according to court documents. Furthermore, these Xarelto lawsuits make a common allegation that Janssen Pharmaceutical and Development, the company responsible for manufacturing and marketing Xarelto, failed to share its knowledge of the drug’s defects, according to court documents. Given that the drug has no known antidote to stop severe bleeding, which is known by the pharmaceutical company and the public, plaintiffs assert the severe bleeding risks should have been clearly communicated to medical professionals and consumers, according to court documents.
Plaintiffs in this case include individuals who allege they have suffered from severe bleeding events, as well as family members who allege they have lost loved ones as a result of Xarelto side effects, according to court documents. The U.S. District Judge assigned to the case is Eldon E. Fallon.
The multidistrict litigation is still in very early stages and attorneys handling Xarelto lawsuits are accepting new claims at this time, according to the Onder Law Firm. The next status conference is scheduled for May 13 at 9 am.
Lawyers representing individuals and families around the nation in Xarelto lawsuits believe that individuals and the families of individuals who experienced internal bleeding, stroke, or another serious health problem while taking Xarelto may be entitled to real compensation by filing a Xarelto lawsuit. Nationally-renowned for groundbreaking work in drug and product safety litigation against multi-billion dollar corporations, the Onder Law Firm’s Xarelto attorneys have committed their significant resources to providing expert legal representation to men and the family members of men who believe they may have grounds to file Xarelto lawsuits. Individuals and family members of individuals who meet this description are entitled to a no-cost, no-obligation consultation through the firm’s Xarelto Contingency Lawsuit website.
The Onder Law Firm welcomes Xarelto lawsuit case inquiries from law firms in regards to handling them or working as co-counsel.
About The Onder Law Firm
Onder, Shelton, O’Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The pharmaceutical and medical device litigators at The Onder Law Firm have represented thousands of Americans in lawsuits against multinational conglomerates from products liability for manufacture of defective or dangerous products to deceptive advertising practices. Other firms throughout the nation often seek its experience and expertise on complex litigation. It is also a recognized leader in products liability cases such as window blind cord strangulation. The Onder Law Firm offers information from attorneys handling Xarelto lawsuits athttp://www.XareltoContingencyLawsuit.com.Link: http://www.prweb.com/releases/xarelto-attorneys/bleeding-lawsuit/prweb12634104.htm
-
Fraudulent Misrepresentation Alleged in Xarelto Lawsuit
Apr 9, 2015 | Injury Lawyer News
By Jacky Gale
A new Xarelto lawsuit has been filed against Janssen Research & Development, Johnson & Johnson, Janssen Pharmaceuticals, and Bayer Healthcare Pharmaceuticals, Inc., et al. The complaint was filed on behalf of Lola Carson, an Ohio resident, and Allen H. Cleland, deceased.
Ms. Carson is the surviving heir of Mr. Cleland, who allegedly passed away as a result of complications caused by the defendant’s medication, Xarelto. The case is currently pending in the U.S. District Court for the Southern District of Ohio and the plaintiff is demanding damages in excess of $75,000 for economic and non-economic losses.
Plaintiff suffered fatal bleeding event
According to the lawsuit, Mr. Cleland, who was born in 1935, began using Xarelto in August 2012. He was prescribed the medication to reduce potential complications of atrial fibrillation, a condition in which a disruption in the electrical system of the heart results in irregular or rapid heart contractions. He continued using the medication as directed by his doctor until March 2013.
On March 28, 2013, the decedent suffered a serious bleeding event. His healthcare team diagnosed him with an intracranial hemorrhage, or bleeding on the brain. Bleeding onto the brain tissue is one possible cause of stroke. The decedent’s surviving heir demands compensation for Mr. Cleland’s severe and permanent personal injuries, pain, suffering, emotional distress, and death. She claims that his injuries and subsequent death were a direct result of Xarelto.
Xarelto (rivaroxaban) uses
Xarelto is a blood-thinning medication that was developed by the defendants as a possible alternative to the gold-standard of blood thinners, Coumadin (warfarin). The newer generations of blood-thinning medications are intended to eliminate some inconveniences associated with warfarin, such as regular blood monitoring and dietary restrictions.
Xarelto may be prescribed to individuals who have or are at risk of developing deep vein thrombosis (DVT), a condition characterized by the formation of blood clots. It is also prescribed to patients such as Mr. Cleland who have atrial fibrillation. With atrial fibrillation, the upper chambers of the heart tend to shake, rather than contract properly, and the ventricles may pump abnormally. Since the capability of the heart to pump all of the blood out to the rest of the body is compromised, blood can accumulate and may form a blood clot. Blood clots can become a life-threatening condition. Xarelto and other blood thinners work by reducing the possibility that the blood will clot.
Surviving heir’s allegations
Although many patients can safely take blood-thinning medications, there are potential complications. According to Ms. Carson’s complaint, Xarelto is an unreasonably dangerous medication and thedefendants engaged in fraudulent misrepresentation when marketing it. When discussing the defendants’ alleged fraudulent misrepresentation, the lawsuit claims they represented to the FDA, the healthcare community, and to patients that Xarelto had been proven safe in clinical tests.
However, the complaint goes on to allege that the defendants had in fact concealed their knowledge ofXarelto bleeding risks, that they had not conducted adequate safety trials, and that they engaged in aggressive advertising campaigns that overstated the efficacy of the drug while understating the risks.
Specifically, one of the risks of Xarelto that allegedly led to the death of Mr. Cleland is that unlike warfarin, there is no antidote for Xarelto. This means that if a patient suffers a bleeding event, such as an intracranial hemorrhage, doctors cannot administer a reversal agent to prevent death.
Link: http://injurylawyer-news.com/2015/04/fraudulent-misrepresentation-alleged-xarelto-lawsuit/
-
Coordination of Xarelto Bleeding Lawsuits Sought Between State and Federal Courts
Apr 9, 2015 | About Lawsuits
By Austin Kirk
As a growing number of Xarelto lawsuits continue to be filed on behalf of individuals throughout the country who have suffered severe or fatal bleeding problems, the parties involved in the cases are continuing to work to coordinate the litigation between the state and federal courts.
Bayer Healthcare and Johnson & Johnson’s Janssen subsidiary currently face more than 300 personal injury and wrongful death lawsuits over the failure to warn about the bleeding risk with Xarelto. However, it is ultimately expected that several thousand complaints will be filed nationwide over the coming months and years.
In December, the U.S. Judicial Panel on Multidistrict Litigation (JPML) established consolidated proceedings in the federal court system, centralizing all cases before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation. The process is designed to coordinate discovery into common issues that are expected to arise through all federal cases, avoid conflicting rulings from different U.S. District Judges and to serve the convenience of the parties, witnesses and the courts.
In addition to complaints filed in the federal court system, there are several hundred more cases pending in various state courts nationwide, including about 170 pending in Pennsylvania state court, where a Xarelto mass tort was established in January.
Judge Fallon recently held an MDL status conference on April 1, during which plaintiffs’ attorneys and defense attorneys discussed the plan for moving the Xarelto litigation forward.
According to minutes (PDF) issued by the Court following the meeting, Judge Fallon indicates that the parties continue to work on coordination between the MDL and state court actions.
The next status conference before Judge Fallon is scheduled for May 13.Xarelto Bleeding Litigation
Xarelto (rivaroxoaban) is a new-generation anticoagulant introduced in 2011 as a superior replacement for Coumadin (warfarin), which has been the “go-to” medication for prevention of blood clots and strokes among patients with atrial fibrillation for decades.
While all blood thinners carry a risk of bleeding injury, Xarelto has been linked to a surprising number of problems as more and more patients are switched to the novel anticoagulant.
Xarelto has been promoted as superior to warfarin, with the drug makers indicating that it is easier to use, since it does not require regular blood monitoring. However, several recent studies have raised questions about those claims, with researchers suggesting that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
In addition to failing to warn about the risk of bleeding and importance of blood monitoring, plaintiffs claim that drug makers withheld information about the lack of a Xarelto reversal agent, which doctors could use to stop hemorrhaging that may develop among users.
While warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.
Similar allegations were raised in the litigation over Pradaxa, which is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010, one year before Xarelto hit the market. More than 4,000 Pradaxa lawsuits were filed by users of that drug who suffered bleeding injuries.
Following several years of litigation, Boehringer Ingelheim ultimately agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
As part of the coordinated pretrial proceedings in the MDL, it is expected that Judge Fallon will schedule a series of early trial dates, known as “bellwether” cases. While the outcomes of these trials will not be binding on other claims, they are designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation.
If the parties fail to reach Xarelto bleeding settlements following the bellwether trial process, it is possible Judge Fallon may begin remanding hundreds of individual cases back to the U.S. District Courts where they would have originally been filed for separate trial dates.
Link: http://www.aboutlawsuits.com/xarelto-bleeding-lawsuits-coordination-state-federal-courts-80592/
-
Rhode Island Man Sues Xarelto Over Bleeding Risks
Apr 9, 2015 | Righting Injustice
By Jennifer Walker-Journey
A Rhode Island man is suing the makers of the blood thinner Xarelto claiming the manufacturers misled the public by marketing the drug as safe while not revealing the odds of serious bleeding side effects associated with the drug. The lawsuit also claims that no antidote is available to reverse the blood thinning effects once uncontrolled bleeding occurs.
Daniel Hernandez filed his lawsuit against Johnson & Johnson unit Janssen Pharmaceuticals and Bayer Healthcare AG, and several of their subsidiaries that manufacture and distribute Xarelto. The blood thinner, which was initially approved in 2011, is used to prevent strokes in some heart patients, and treat or prevent blood clots in patients undergoing hip or knee replacement surgery. Xarelto was promoted as a safer and more convenient alternative to the long-used warfarin but, unlike warfarin, there is no reversal agent.
According to Hernandez’ complaint, the defendants received a warning letterfrom the Food and Drug Administration (FDA) in June 2013 requesting that they cease promotion of Xarelto because the medication had been linked to more than 1,000 adverse event reports, 65 of which had resulted in death.
Hernandez claims he suffered injuries after using Xarelto. His lawsuit cites product liability and he is seeking damages in excess of $50,000 plus attorneys’ fees and costs.
Hernandez’ lawsuit is one of thousands that have been waged against the makers of Xarelto claiming the drug companies failed to warn of the serious and life threatening bleeding risks associated with the drug , including gastrointestinal bleeds, brain hemorrhages, and rectal bleeding.
Link: http://www.rightinginjustice.com/news/2015/04/09/rhode-island-man-sues-xarelto-over-bleeding-risks/
-
MEYERKORD & MEYERKORD Currently Representing XARELTO Cases
Apr 9, 2015 | St. Louis Personal Injury Lawyer
By Meyerkord & Meyerkord LLC
Xarelto is a new-age anticoagulant created by Bayer and Janssen Pharmaceuticals to help people with the following conditions:
A-Fib
Deep Vein Thrombosis
Recent SurgeryPatients At Risk For Stroke
Furthermore, Xarelto is a more popular choice among users because it offers a more convenient option for patients by not needing routine blood monitoring, and opening a broader range of food while taking it. Tragically, although Xarelto gives patients more life-style choices and ease, it is damaging as well. For instance, many patients are experiencing life threatening bleeding episodes while taking Xarelto. Likewise, there is no antidote to stop bleeding once it's began unlike other blood thinners on the market. Coumadin bleeding can be stopped with a dose of vitamin K, yet currently Xarelto makers have no such mechanism to stop patients from bleeding to death. Now, some patients are becoming severely injured, and even dying as a result of taking Xarelto. Victims and their family members are seeking answers, and looking to the justice system to help.
The skilled St. Louis personal injury attorneys at Meyerkord & Meyerkord are currently representing Xarelto cases from all over the United States, and would like to help you or a family member if this drug has injured you. Please call us today for a free consultation regarding your potential drug liability and consumer protection case.
Link: http://www.stlouis-personalinjury.com/Blog/2015/April/Meyerkord-Meyerkord-currently-representing-Xarel.aspx
-
Ala. Man Sues Pharmaceutical Giants over Xarelto Bleeding
Apr 9, 2015 | Top Class Actions
By Amanda Antell
Alabama plaintiff Richard E. is suing Bayer and Janssen Pharmaceuticals for the injuries he allegedly suffered after taking Xarelto. Richard claims that in direct result of taking the medication, he suffered severe Xarelto bleeding injuries that required emergency hospitalization.
Like millions of other Americans, Richard suffers from atrial fibrillation and is at a high risk for stroke. To prevent this, Richard’s physician prescribed him Xarelto on Dec. 17, 2012, after reviewing the defendants’ advertisements of the drug’s efficiency.
According to the Xarelto bleeding lawsuit, Richard followed all instructions provided by his physician and took heed of the drug’s warning label. Initially, he responded well to Xarelto for his treatment therapy, but quickly faced problems soon after starting the drug. A few weeks into his prescription, he allegedly experienced one of the drug’s side effects and suffered a Xarelto bleeding event.
On Jan. 7, 2013, Richard suffered a brain bleed injury and was immediately hospitalized. Upon his initial arrival, his bleeding injuries reportedly became worse which resulted in him falling into a coma for approximately two weeks. After awakening, he was transferred into the hospital’s rehabilitation wing for one month where he had to relearn how to walk and feed himself.
While Richard was eventually discharged from the hospital, he still reportedly suffered from vision deficit from the aftermath of his Xarelto bleeding injury. Prior to taking Xarelto, Richard had no history of bleeding injuries, nor was he suffering from any kind of medical condition that would have caused him to suffer this adverse event. At no point before or after his prescription was Richard aware of the possibility of internal bleeding events, or any other Xarelto side effects.
As mentioned before, Bayer and Janssen had advertised Xarelto to be overtly superior to any other anticoagulant on the market, promising fast treatment and minimal dose management. However, the defendants failed to mention that Xarelto lacked a stopping agent in the case of bleeding event like that of Richard’s. The Xarelto bleeding lawsuit further alleges that Richard’s Xarelto bleeding was an avoidable injury and that he never would have taken Xarelto if he had known about the possibility of Xarelto bleeding.
Richard is suing Janssen and Bayer Pharmaceuticals for being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous drug. The charges include negligence, false advertising, concealing information, and misrepresenting a product.
Overview of Xarelto Complications
Janssen Pharmaceuticals and Bayer Pharmaceuticals released Xarelto as a joint venture, in order to break into the lucrative anticoagulant market, after seeing the initial success of Pradaxa. Xarelto was approved by the FDA in 2011, a year after Pradaxa’s approval in 2010, and was meant to prevent stroke in patients who had recently come out of knee surgery or were suffering from atrial fibrillation. The timing of Xarelto’s release is interesting to note, because its rise to popularity came at a time when Pradaxa was facing extreme scrutiny for adverse bleeding events. Despite having similar pharmaceutical makeup to Pradaxa, Janssen and Bayer allegedly continued to promote Xarelto with the intent of dominating the anticoagulant market.
However, Xarelto fell from glory after it was discovered that it had the same design defects as Pradaxa. As mentioned before, Xarelto has no stopping agent in the case of a bleeding injury, which could be fatal for patients. Medical experts state that while Xarelto and the other new generation anticoagulants may be faster and more convenient than the original anticoagulant, Warfarin, they do not have as many safety features. In the case of a Warfarin bleeding injury, all the patients have to do is apply vitamin K to stop the event. Additionally, Warfarin patients have to undergo frequent doctor appointments to monitor and adjust the dosage of the medication.
Medical experts state that if Xarelto and Pradaxa patients would have been required to go through monitored dose adjustments, then many bleeding injuries could have been avoided. Furthermore, Janssen and Bayer would also have been able to avoid facing bleeding lawsuits from plaintiffs who were allegedly injured by the drug.
This Xarelto lawsuit is Case No. 2:15-cv-00183-EEF-MBN, in the U.S. District Court for the Northern District of Alabama, Southern Division.
Link: http://topclassactions.com/lawsuit-settlements/lawsuit-news/53270-ala-man-sues-pharmaceuticals-giants-xarelto-bleeding/
-
Does Xarelto Cause Uncontrollable Bleeding?
Apr 9, 2015 | The Legal Examiner
By Shezad Malik MD JD
The short answer is yes, if you believe the allegations in the over 300 lawsuits filed to date. Xarelto is one of the newer oral anticoagulant medications that has been approved by the FDA. The federal Xarelto personal injury and product liability claims are centralized before U.S. District Judge Eldon E. Fallon in the Eastern District of Louisiana.
Xarelto is one of the newer oral anticoagulant medications that has been approved by the FDA.
Xarelto Personal Injury Bleeding and Death Cases Over 300
Bayer and Johnson & Johnson (J&J) as co-developers, are exposed to at least 315 bleeding cases in the federal multi-district litigation (MDL), according to a Docket Report issued by the U.S. Judicial Panel on Multidistrict Litigation on March 16, 2015, with thousands more on the way.
According to experts, the total tally may exceed several thousands before the litigation is settled. The plaintiffs blame the manufacturers for the severe, and often fatal bleeding injuries that were caused by Xarelto side effects.
Xarelto Lack of Adequate Warnings
Plaintiffs allege that the drug makers neglected to adequately warn about the risks associated with the new-generation anticoagulant and the lack of an effective antidote for Xarelto, in the event of uncontrollable bleeding.
Xarelto Uncontrollable Bleeding Risks
Xarelto (rivaroxoaban) is a new-generation anticoagulant approved by the FDA in 2011 as a replacement for Coumadin (warfarin). Coumadin, has been the “gold standard” medication for prevention of blood clots and strokes in patients with atrial fibrillation, a common heart rhythm abnormality for the past 60 years.
All blood thinners carry a risk of bleeding, BUT Xarelto has been linked to a severe injuries as more patients are transferred over to the new blood thinner.
Xarelto has been touted as a safer alternative to Coumadin, with the drug makers promoting that it is easier to use, since it does not require regular blood tests to measure its effectiveness.
According to several recent studies there are concerns about those claims, with researchers noting that Xarelto blood tests may help doctors identify patients at the greatest risk of bleeding. Additionally, plaintiffs blame the drug makers for withholding critical information about the lack of a Xarelto reversal agent, which doctors could use to stop uncontrollable hemorrhaging.
Coumadin’s blood thinning effects can be quickly reversed in an emergency, there is no similar antidote for Xarelto.
Xarelto is a $Billion Dollar Blockbuster Drug
According to court documents, Xarelto has raked in over $2 billion in sales nationwide with over one million prescriptions written by 2013, two years after the drug’s introduction into the market. Xarelto is a huge cash cow for the pharma division at J&J.
Xarelto, has grabbed a 32 percent market share in the highly competitive anticoagulant market, significantly ahead of Boehringer’s Pradaxa and Bristol-Myers Squibb’s Eliquis, the other two new anticoagulants in the market. The Xarelto pony is way ahead in the three way pony race.
Company sales representatives continued to tout Xarelto as a convenient alternative to the established blood-thinner warfarin, but by the end of 2012, there had been 2,080 Xarelto-related injuries, including 151 deaths.
Xarelto Federal MDL Lawsuits
The MDL has an important role in streamlining the litigation process, as all plaintiffs and defendants are under one roof, coordinate discovery and the bellwether trials can be set to determine the strength of the claims.
As part of the coordinated pretrial proceedings, it is common in complex pharmaceutical and medical device mass tort litigation, that a small group of cases will be selected as “bellwether” cases.
These lawsuits will be prepared for early trial dates to help the parties determine how juries may respond to certain evidence and similar testimony that is likely to be repeated throughout the litigation.
If the parties fail to negotiate a settlement or resolve the litigation following pretrial proceedings, Judge Fallon may remand cases back to the U.S. Districts where they were originally filed for separate trial dates in the future.
Xarelto State Court Actions
There are several hundred more cases pending in various state courts nationwide, including about 170 pending in Pennsylvania state court, where a Xarelto mass tort was established in January.
Link: http://fortworth.legalexaminer.com/fda-prescription-drugs/does-xarelto-cause-uncontrollable-bleeding/
-
Xarelto makers sued by Texas woman
Apr 8, 2015 | Williams Kherkher Attorneys
A plaintiff from Texas recently filed a lawsuit against Xarelto makers in St. Clair County Circuit Court claiming she suffered injuries as a result of using the potentially dangerous drug, Madison-St. Clair Record stated on April 6.
Reports said Lola Daniel on March 26 filed her lawsuit against Janssen and Bayer affiliates. In her lawsuit Daniel claimed she suffered personal injuries and economic damages after being prescribed Xarelto. Daniel’s lawsuit alleged that the defendants are liable for designing, researching, producing, testing, advertising, and selling the potentially hazardous and defective drug.
She is seeking $4.5 million in damages.
The pharmaceutical liability lawyers of Williams Kherkher help people who are suffering from the potentially dangerous side effects of Xarelto. If you or a loved one is in such a situation, we may be able to work for you to secure treatment funds from negligent drug companies. Learn more about your options from us today by calling (800) 220-9341.
Link: http://www.williamskherkher.com/blog/2015/04/08/xarelto-makers-sued-by-texas-woman/
-
Xarelto Causes Life-Threatening Internal Bleeding, Lawsuit Claims
Apr 7, 2015 | Top Class Actions
By Melissa LaFreniere
The global anticoagulant leader Xarelto is under scrutiny once again as an Alabama resident files lawsuit against its manufacturer Janssen Pharmaceutical, alleging the drug causes life-threatening internal bleeding.
Plaintiff Catherine C. claims she experienced irreversible gastrointestinal Xarelto bleeding after using the medication for only one month and that she was not adequately warned of the dangerous side effects it could cause.
The Xarelto lawsuit claims that under the direction of her physician, Catherine was encouraged to take Xarelto to treat pulmonary embolism (PE) but instead of helping the issue, the plaintiff reports severe and permanent personal injuries occurred due to Xarelto bleeding. The plaintiff further claims that the defendants “under-reported, underestimated and downplayed the serious dangers of Xarelto.”
Catherine states that had she known about the real risks involved with taking the drug Xarelto, she never would have purchased or used it.
The Xarelto lawsuit seeks to award more than $75,000 in physical and emotional damages sustained by Catherine.
Xarelto Risks
The blood thinner Xarelto was FDA approved in 2011 to help reduce the risk of forming blood clots after surgery. The defendants also claim that taking Xarelto not only helps treat pulmonary embolisms but also helps “reduce the risk of the condition occurring again.” However, the plaintiff reports that the representations made from the manufacturer are in fact false. And the growing numbers of Xarelto “Serious Adverse Event” (SAE) reports being filed with the FDA seem to agree with her.
At the end of its first full year on the market, more than 2,000 SAE reports of Xarelto complications were filed with the FDA. Of those reported events, 151 resulted in death.
Some of the side effects of Xarelto taking include but are not limited to: Deep vein thrombosis, Pulmonary embolism, Abdominal bleeding, Gastrointestinal bleeding, Brain hemorrhaging, Abnormal liver function, Reduced platlet levels, DizzinessHemorrhaging in the eyes, Low Blood Pressure, Nose Bleeds, Rectal Bleeding, Headache, Muscle Pain, Rapid HeartbeatBruisingEdemaFailure to Warn
The Xarelto lawsuit alleges that the defendant “failed to warn and disclose to patients that there is no agent to reverse the anticoagulation effects of Xarelto and that if serious bleeding occurs, it may be irreversible, permanently disabling and life threatening.”
According to the defendant’s website, more than 11 million prescriptions have been written for Xarelto in the U.S. alone — prescriptions that, just like the one Catherine was encouraged to take to treat pulmonary embolism, puts patients at risk for uncontrollable Xarelto bleeding.
Catherine believes the manufactures were negligent in their warnings associated with the use of Xarelto. “It was both technically and economically feasible to provide a safer alternative product that would have prevented the harm suffered by the Plaintiff,” her Xarelto lawsuit says.
The Xarelto Lawsuit is Case 4:15-cv-00474-VEH in the U.S. District Court Northern District of Alabama.
Link: http://topclassactions.com/lawsuit-settlements/lawsuit-news/53214-xarelto-causes-life-threatening-internal-bleeding-lawsuit-claims/
-
Apr 7, 2015 | The Lieser Law Firm
Xarelto Lawsuits in Missouri and Illinois
Many of you may have seen commercials for and against the drug, Xarelto, on TV. Xarelto is blood-thinning drug used to prevent blood clots in patients who have had surgery or are at risk for a blood clot or stroke. Anticoagulants, such as Xarelto, are supposed to make sure that your blood will continue to circulate through your body. Millions of Americans rely on blood thinners every day, but Xarelto is a fairly new drug on the market. Unfortunately, Xarelto comes with a unique set of health risks that have brought on product liability lawsuits for bleeding.
Xarelto and Blood Thinning Drugs
Before Xarelto, Coumadin was the drug of choice for thinning blood. Even though it has been effective, Coumadin requires that patients adjust their diets and make constant trips to the doctor’s office for blood tests to see if the level of the dose needs to be adjusted. Xarelto, and other drugs like it, have become very popular because of their convenience of not having to make constant trips to the doctor.
The bad news is that these new drugs were pushed quickly through the FDA approval process and the risks that came with them were not researched enough. Currently, reports on adverse events are showing that patients taking Xarelto are in danger of a severe bleeding episode. Coumadin has an antidote for this; Xarelto does not. This means that once you start to hemorrhage or suffer with internal bleeding, there is no way for it to be stopped. Patients who have taken Xarelto may suffer or perhaps die as a result of severe internal bleeding. Xarelto Studies
A 2011 study that was published in the New England Journal of Medicine showed that Xarelto is just as effective as Coumadin. However, because Xarelto does not have an antidote for its blood-thinning properties, it is significantly more dangerous than other blood thinners. An FDA warning letter was sent to the makers of Xarelto in 2013 for not warning patients of the high risk of bleeding.
Bayer and Janssen, the makers of Xarelto, neglected to inform customers of the seriously dangerous risks that come with the drug. They still have not provided the medical community with information about how to stop dangerous bleeding from Xarelto. They are obviously putting profits before safety, and by doing so they have put the lives of millions of Americans in danger.
Xarelto Attorneys in Missouri and Illinois
Patients and relatives of people who have experienced severe internal bleeding episodes while taking Xarelto may be entitled to compensation for pain and suffering through a Xarelto lawsuit. Our attorneys here at the Lieser Law Firm will be more than happy to answer any questions you and your family may have. Xarelto lawsuits are brought on a contingency basis. This means that there are no legal feels unless we win the lawsuit for you.
Filing a personal injury lawsuit against pharmaceutical companies may be the only way we can hold them accountable for their mistakes in not informing the public about the risks of their drugs.
Link: http://www.lieserlawfirm.com/blog/2015/04/xarelto-bleeding-risks/
-
Xarelto still Brings Big Money to Johnson & Johnson
Apr 6, 2015 | Xarelto Lawsuit
By Flood Law Group, LLP and Gacovino, Lake & Associates, P.C
A growing number of Americans have claimed that Johnson & Johnson, makers of the blood thinner Xarelto, failed to warn of serious and potentially fatal internal bleeding side effects of the drug. In fact, at least 86 Xarelto lawsuits have been consolidated into a multidistrict litigation (MDL) in Louisiana. Despite the negative attention garnered by these lawsuits and allegations, the Xarelto still earned more than $1 billion for J&J last year.
In light of Xarelto profits reflected in Johnson & Johnsons published 2014 report to shareholders, it seems that the allegations and lawsuits concerning Xarelto side effects have not had too severe an effect on the company’s bottom line. Xarelto sales topped $1.5 billion in 2014, nearly two times the $864 million it earned in 2013.
Most credit for the high Xarelto sales can go to aggressive direct-to-consumer marketing. In Xarelto commercials, some of which feature celebrities, a strong focus is placed on the convenience of Xarelto when compared to other anticoagulants. While many blood thinner patients need to undergo routine blood monitoring to ensure proper dosing, Xarelto ads tell prospective users that they won’t need to check in for a monthly blood test.
In Xarelto lawsuits, many plaintiffs are claiming that the advertisements boasting the safety and convenience of Xarelto misled them. Though there is a risk of internal bleeding with all blood thinners, the truth is that some anticoagulant bleeds can be stopped with a timely dose of an antidote.Xarelto internal bleeding has no reversal agent.
If you or someone you love has suffered serious internal bleeding or even death as a result of Xarelto side effects, you could be entitled to compensation for your damages and suffering. For more information on Xarelto lawsuits, contact an experienced attorney today.
Link: http://www.xareltolawsuit.com/news/xarelto-still-big-money-johnson/
-
Was Xarelto Approved Based on Faulty Data?
Apr 6, 2015 | The Legal Examiner
By Eric T. Chaffin
Just how accurate are the clinical trials that are submitted to the FDA for drug approvals?According to a recent study in JAMA Internal Medicine, there may be a number of errors, or “departures from good clinical practice” in these studies. These are seldom reported in peer-reviewed literature, leaving doctors and consumers in the dark. This could be particularly serious, as many of the clinical trials in the studies were those that formed the basis for later drug approvals.
One of those drugs—Xarelto—was approved despite what has now been called a study full of transgressions, a study that was deemed unreliable by the FDA.
FDA REGULARLY INSPECTS CLINICAL STUDY SITES
Unknown to most consumers of prescription drugs, the FDA, as part of its approval process, inspects several hundred clinical sites performing biomedical research on human participants every year. They do occasionally find “evidence of substantial departures from good clinical practice and research misconduct,” according to the study in JAMA.
The problem is the FDA has no established method of communicating these findings to the scientific community. That means that there is a chance that scientists, doctors, and consumers remain in the dark about them, as they are never reported in the journals in which the studies are published.
JAMA STUDY SHOWS ERRORS IN STUDIES NEVER REPORTED
Researchers examined documents dated from January 1, 1998 to September 30, 2013. These documents described inspections of clinical trial sites at which the FDA found evidence of problems. The researchers then checked to see if the inspection documents could be linked to specific published clinical trials.
Results showed the following:
• A total of 57 published clinical trials were found to have evidence of one or more problems.
• These problems included falsification or submission of false information, problems with adverse events reporting, protocol violations, inadequate or inaccurate record keeping, failure to protect the safety of the patients, and other violations.
• Only four percent of the publications that resulted from these trials ever mentioned the problems found during the inspections.
• No corrections, retractions, expressions of concern, or other comments acknowledging these issues were ever included in the other published studies.The researchers concluded that even when the FDA finds “significant departures from good clinical practice, those findings are seldom reflected in the peer-reviewed literature, even when there is evidence of data fabrication or other forms of research misconduct.”
ONE OF THE STUDIES RIDDLED WITH PROBLEMS WAS ON XARELTO
Unfortunately, the research, conducted by Charles Seife of the Arthur L. Carter Institute of Journalism at New York University, gave few clues as to just which drugs were involved in these error-ridden clinical trials. The inspection records had redacted and blacked out sections that concealed the drugs and their manufacturers. There was one, however, that was not blacked out—Xarelto (rivaroxaban).
It turns out that one of the studies that supposedly showed Xarelto to be an effective and safe blood-thinner was full of departures from good clinical practice. So called “RECORD 4” (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep-Venous Thrombosis and Pulmonary Embolism 4) was riddled with problems, including “systematic discarding of medical records,” according to Seife, falsification, and “concerns regarding improprieties in randomization.”
Yet despite all these issues, the study was published in the respected medical journal, Lancet, in May 2009—with none of the errors or problems reported. It seems to indicate that Xarelto is effective for preventing blood clots after knee replacement surgery, even though the FDA found that researchers faked some of the data and destroyed some medical records. Seife noted in his report that the FDA found RECORD 4 unreliable, yet they ended up approving Xarelto anyway, based on other trials that were found to have fewer problems.
Plaintiffs who took Xarelto and then suffered from serious side effects like severe gastrointestinal bleeding may be eligible to file a personal injury lawsuit.
Link: http://newyork.legalexaminer.com/defective-dangerous-products/was-xarelto-approved-based-on-faulty-data/
-
Intracranial Hemorrhage Subject of Xarelto Lawsuit
Apr 3, 2015 | Drug Reporter
By Eisbrouch Marsh LLC
For patients suffering from the condition known as atrial fibrillation – or “A-fib” – an anti-coagulant drug is often used to help prevent the formation of deadly blood clots. For generations, doctors prescribed the drug known as warfarin to A-fib patients, until the newer blood thinning drug Xarelto was introduced to the market in 2011.
While some have lauded Xarelto for reducing the monthly bloodwork requirements, others have objected to its blood thinning capabilities for which no antidote is currently available. Moreover, the use of Xarelto has been linked with deadly internal hemorrhaging – particularly during surgery – prompting the filing of several lawsuits against its manufacturer Janssen Pharmaceuticals and Johnson & Johnson.Plaintiff alleges wrongful death of family member
In a Xarelto lawsuit filed on March 26, 2015 in United States District Court for the Southern District of Ohio, the plaintiff – and surviving heir – of a deceased Xarelto patient has alleged that defendants unlawfully marketed the drug as safe when each knew or should have known of the risks of hemorrhage. According to allegations, the deceased patient suffered from atrial fibrillation and was prescribed Xarelto in order to curtail the increased risk of developing a life-threatening blood clot.
For approximately one year, the decedent took Xarelto under the supervision of his physician. On or about March 28, 2013, the decedent experienced an intracranial hemorrhage, for which no antidote was possible. As a result he suffered severe personal injuries and emotional distress – and eventually succumbed to his condition.Xarelto lawsuit allegations
The plaintiff continues her allegations by detailing the allegedly exorbitant marketing budget earmarked for the Xarelto product, with virtually no focus on the dangers of the drug. In her complaint, the plaintiff points to the pre-market studies conducted on Xarelto, which were conducted on knee and hip replacement patients in need of a blood thinner to control the risk of clotting.
In those studies, the plaintiff asserts that Xarelto has shown no superior qualities to the traditional drug known as warfarin, and was only used in a limited panel of patients. Nonetheless, the drug is marketed as far superior to the outmoded warfarin – which requires inconvenient weekly blood monitoring – and a safer alternative for patients suffering from A-Fib.
Alarmingly, the plaintiff also cites a finding in clinical studies that “bleeding from gastrointestinal sites, including upper, lower, and rectal sites, occurred more frequently in the [Xarelto] group, as did bleeding that led to a drop in the hemoglobin level or bleeding that required transfusion.”
This lawsuit is one of hundreds alleging dangerous internal bleeds caused by Xarelto. The blood thinning drug Pradaxa has also been named in several thousand lawsuits involving similar allegations of concealed bleeding risks. To date, Xarelto cases remain individual in nature, and no multidistrict litigation (MDL) has been set up. However, it is not uncommon for these types of cases to move to MDL as the number of plaintiffs increases.
Link: http://drugreporter.com/2015/04/intracranial-hemorrhage-subject-xarelto-lawsuit/
-
Bleeding-Induced Heart Attack Leads to Xarelto Class Action Lawsuit
Apr 10, 2015 | The Legal Examiner
By Eric T. Chaffin
All U.S. federal Xarelto lawsuits were consolidated in one court in the Eastern District of Louisiana in December 2014. Now, plaintiffs have filed a new Xarelto class action case in Canada, seeking to gain compensation for Canadian patients who took the drug and later suffered serious side effects.
The lead plaintiff in the case is Betty Samson, who according to her complaint, suffered uncontrolled bleeding after taking Xarelto in 2012. When doctors weren’t able to stop the bleeding, she went into cardiac arrest.
According to the Calgary Sun, another Xarelto class action lawsuit is forthcoming in Ontario. The lead plaintiff allegedly suffered serious bleeding after taking the anticoagulant drug, and later bled to death. Both plaintiffs name joint manufacturers Bayer and Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, as defendants.NUMBER OF XARELTO LAWSUITS CLIMBING
So far, about 220 Xarelto lawsuits are pending throughout the United States. A so-called “new generation” blood thinner, Xarelto was approved in 2011 for preventing blood clots in patients going through hip and knee replacement surgeries, and later in 2012 for reducing the risk of stroke in patients with non-valvular atrial fibrillation.
When manufacturers released the product on the market, they advertised it as a superior alternative to warfarin, the leading anticoagulant. Unlike patients taking warfarin, those taking Xarelto didn’t have to go through blood monitoring or alter their diets. Defendants failed to highlight the fact that there was no readily available antidote to Xarelto bleeding, however. While patients taking warfarin who suffer uncontrollable bleeding can be treated with vitamin K injections, there is apparently no such solution for Xarelto bleeding.
Recent studies have suggested that many patients taking Xarelto, would have benefitted from blood monitoring to keep tabs on how they were responding, particularly patients with poor kidney function.
CANADA RECEIVES OVER 1,000 XARELTO ADVERSE EVENT REPORTS
Health Canada has so far received about 1,100 reports of problems connected to Xarelto, with twelve of those involving patient deaths. According to her case, Samson came close to death when her doctors had trouble stopping her Xarelto bleeding. She includes in her complaint reports from Germany that linked Xarelto to 130 deaths between 2012 and 2013.
Xarelto lawyers in Canada have been approached by other claimants with similar experiences. According to the Calgary Sun, one of the claimants lost her mother when she bled to death in the shower. This is the case that will likely represent the other class action from Ontario.
A class action lawsuit differs from an individual lawsuit in that one plaintiff or group of plaintiffs represents a larger group seeking compensation from the defendants. The issues at dispute are the same among all members of the class—in this case, all members would have been injured by Xarelto and suffered uncontrolled bleeding. There must be enough members in the class to make individual cases impractical. Any jury award is split up among the members.
Link: http://newyork.legalexaminer.com/defective-dangerous-products/bleeding-induced-heart-attack-leads-to-xarelto-class-action-lawsuit/
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Plaintiff Attorney Press Releases
Plaintiff Attorney Blogs
OUS Litigation
Full Text of Stories Below
Add recipients
Suggested